Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2011-12-27 Major Shareholding Noti…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Change in substantial holding 3 pages 144.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder, including dates and share quantities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management information, but a regulatory disclosure about shareholding changes.
2011-12-27 English
Change of Director`s Interest Notice 3 pages 69.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of securities held before and after the change, nature of the change, and related parties. This is a clear report of personal share transactions by a company director. The document is not a full financial report, earnings release, or management report, but specifically a director's dealing notice. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length is 4213 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or a full report.
2011-12-18 English
Change of Director`s Interest Notice 2 pages 64.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3261 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2011-12-18 English
MUH becomes Shareholder in CYC Imaging Joint Venture 3 pages 162.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 19 December 2011 from Cyclopharm Ltd regarding Macquarie University Hospital becoming a shareholder in a joint venture called Macquarie Medical Imaging. It details the shareholding structure, the strategic importance of the partnership, and background information about the companies and technologies involved. There are no financial statements, quarterly or annual results, nor any regulatory filings or voting results. The content focuses on a corporate partnership and joint venture shareholding update, which fits best under Capital/Financing Update (CAP) as it relates to changes in ownership and capital structure of a joint venture. The document length (6573 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2011-12-18 English
Cyclopharm Receives Approval from United States FDA 2 pages 350.5KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 13 December 2011 from Cyclopharm Ltd, reporting FDA approval to commence Phase 3 clinical trials for their product Technegas. It discusses the clinical trial design, expected costs, and future marketing approval timeline. The content is an announcement of a regulatory milestone and business update rather than a financial report, earnings release, or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document is about a regulatory approval and clinical trial commencement, which fits best under a general regulatory announcement category. It is not a report publication announcement since it does not mention a report being attached or published. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2011-12-12 English
Correction - Number of Issued Shares 9 pages 487.6KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a New Issue Announcement filed with the ASX (Australian Securities Exchange). It details the issuance of new shares, including the number of shares, issue price, purpose of the issue, and other related information. The document also includes a correction regarding the number of issued shares and an updated Appendix 3B attached. The content focuses on share issuance and capital raising activities, with no financial statements or detailed financial performance data. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an annual or interim report, earnings release, or regulatory filing of another type. Therefore, the correct classification is CAP with high confidence.
2011-12-11 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.